Hypertension Drugs Market

Hypertension Drugs Market: Overview

The Hypertension Drugs Market is valued at USD 25.44 Bn in 2026 and is projected to reach USD 33.9 Bn, growing at a CAGR of 4% by 2033. Some main factors driving this market include expanding activities by major market participants, the increasing prevalence of pulmonary arterial hypertension, adoption rates, the accessibility of reimbursement, and the introduction of generic drugs. The American Lung Association estimates that every year in the United States, 500 to 1000 new cases of PAH are diagnosed. Cirrhosis of the liver, connective tissue disorders, congenital cardiac defects, and infections, including HIV and schistosomiasis, are other ailments connected to hypertension. In the near future, it is anticipated that the high incidence and prevalence of the ailment and its severity and threat to lifespan will contribute to the rising need for pulmonary arterial hypertension medications.

Throughout the predicted period, possibilities presented by the growing number of patents expiring can be taken advantage of to provide generics at reasonable prices. It is anticipated that increased R&D efforts and regulatory approvals in established and developing markets will greatly increase the demand for and consumption of generic drugs. In March 2019, the first generic version of Remodulin treprostinil injectable was only released in the United States by Sandoz (a branch of Novartis). During the fiscal years 2020–21, Cipla introduced generic ambrisentan in Europe and developing countries. Teva Pharmaceutical Industries Ltd., on the other hand, debuted the generic version of Letairis (ambrisentan tablets) in the U.S. in May 2019.

The number of people with high blood pressure and hypertension is alarmingly rising due to sedentary lifestyles and adopting bad eating habits. Hypertension medications are now widely used for the prompt prevention and treatment of hypertension as a result of this. In keeping with this, the market is expanding due to the increased use of combination medicines. These cutting-edge treatments treat different hypertension mechanisms with a combination of medications, which lowers the risk of cerebrovascular accidents and coronary problems. Other growth-inducing substances include the development of imidazolines, monatepil, and neutral endopeptidase inhibitors.

Hypertension Drugs Market: COVID-19 Impact

Market participants claimed that the COVID-19 pandemic substantially impacted operational activities, financial performance, and operational results. These included slowed-down demand, supply-chain issues, delays in clinical studies, and fewer new patient visits. For instance, Gilead cited negative effects on its clinical investigations, including the inability of the business to start and finish trials within the anticipated time frames. Most of Gilead's clinical trials involving new subjects were delayed in 2020 due to restrictions on patient visits. The epidemic also interfered with regulatory examinations and inspections, which affected market participants' capacity to introduce new commercial items. With the patients' limited ability or inclination to start new therapies and to access and seek assistance from healthcare providers, the market had low demand. The market gradually recovered by 2021. With the large firms' efforts to maintain a steady supply of stock for current clients, the pandemic had little to no detrimental effects on the sales of medications for treating hypertension.

Global Market for Hypertensive Drugs to be Driven by Launch of New Disease-Modifying Therapies

Innovative hypertensive medications and pharmacological therapies are anticipated to produce positive results since they successfully stop illness development. The introduction of new treatments for diseases, including angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, and calcium channel blockers (CCB) throughout the projected period is anticipated to modify the current situation in the worldwide hypertensive medicines market.

Currently, doctors are prescribing more ACE and CHF inhibitors than typical first-line hypertension medications like beta-blockers and diuretics. ACE inhibitors lower mortality and morbidity in people with cardiovascular disease. However, CCBs do not share this benefit. Short-acting CHFs should be avoided, and alternatives should be considered if control cannot be achieved with beta-blockers, diuretics, or ACE inhibitors. ARBs do not cause coughing, in contrast to ACE inhibitors. Therefore, the global market for hypertensive medications is anticipated to be driven by the introduction of novel drug/therapeutic compounds with disease-modifying capabilities and enhanced efficacy and safety in the coming years.

Global Market for Advanced and Effective Drugs to be Driven by Increasing Need

The growing prevalence of cardiovascular diseases (CVD) worldwide and the rising desire for more potent treatments are significant driving forces. Cardiovascular therapies have experienced considerable R&D developments since they were initially presented to the general public. Since then, several innovative treatments have been successfully introduced to the global market. The global market for hypertension drugs may be overcrowded with multiple significant competitors and the growing effect of comparably less expensive generics. However, because of the nature of cardiovascular illnesses (CVD), treatment prospects for patients are getting poorer due to their increasing prevalence. As a result, there is a significant unmet need for treatment in the market, which is expected to be one of the other major driving forces in the global market.

Lack of Awareness to Restrict Market’s Growth

One of the main barriers to the market for pharmaceuticals to treat hypertension is a lack of public awareness of the usage of antihypertensive medications. Sometimes, especially in developing countries, people are oblivious to their health screenings and are unaware of the current high blood pressure situation until they experience severe signs and symptoms. Additionally, people diagnosed with high blood pressure often do not adhere to their prescribed medication schedule and stop taking medication after 1-2 weeks until signs and symptoms reappear, which presents a significant challenge to the market for hypertension medications. A survey shows that 17% of the 112 hypertension patients who had strokes had taken their antihypertensive meds consistently. The market for hypertensive medications may be constrained by a lack of awareness and poor drug adherence.

Hypertension Drugs Market: Segment Overview

Diuretics to Dominate Market due to Improved Efficacy

By encouraging the kidneys to release more sodium into the urine, diuretics aid in removing sodium and water from the body. This lowers blood pressure as the amount of fluid moving through the body reduces. Diuretics are the most commonly used therapeutic drug class for the treatment of hypertension when compared to other therapeutic drug classes because of their great efficacy, low cost, and lack of unwanted side effects. Thiazide diuretics are the mainstay of treatment for hypertension in most patients worldwide. Other forms of diuretics include loop diuretics and potassium-sparing diuretics. For example, according to a study, loop diuretics have FDA approval to be used alone or in conjunction with other anti-hypertensives to treat hypertension. For the aforementioned reasons, the therapeutic class of diuretics is anticipated to grow at the highest rate among all others as cases of hypertension become more commonplace globally.

With Increased Hospitalization of Aging Population, Hospital Pharmacies to Dominate Market

The hospital pharmacies segment is predicted to hold the leading share because these medications are frequently administered following a comprehensive diagnosis, which is frequently carried out at these institutions. This market's expansion can be linked to increased stroke and myocardial infarction cases worldwide and patient preferences for care in hospitals. The hospital pharmacy market is also expanding due to the growing elderly population. This is because elderly people are regularly admitted to hospitals for various chronic conditions and receive their drugs from hospital pharmacies. Additionally, there have been more vehicle accidents worldwide, resulting in patients being admitted to hospitals for an extended period of time. Healthcare providers use hospital pharmacies' medicinal supplies to give these patients easy access to medications. The sector of hospital pharmacy is expanding as a result of this factor.

North America to Acquire Largest Market Share due to Increased Prevalence of Hypertension

North America now owns a significant proportion of the market for hypertensive medications and is anticipated to exhibit a similar trend throughout the projected period due to the high incidence of hypertension and the disorders that cause it in the region. Some key market drivers of the North American hypertension market include the need for rapid and accurate diagnosis and treatment of hypertension, identifying those predisposed to the condition, the presence of technologically advanced healthcare infrastructure, and managing the disease's prognosis. In North America, the United States will have the largest market for hypertensive medications market in the area. The main driver of the hypertensive drug market expansion in the United States is the increased prevalence of hypertension. Following the Center for Disease Control and Prevention, over half of the adults (47 percent, or 116 million) will have hypertension in July 2022. As a result, the rising prevalence of hypertension in the United States is predicted to increase demand for hypertensive medications and spur market expansion. Therefore, it is anticipated that North America will dominate the hypertensive market.

Over the following few years, the market in the Asia Pacific is anticipated to see the quickest growth rate. This is because generic drug use is increasing, important pharmaceutical businesses are nearby, and the healthcare system is evolving. For instance, the generic equivalent of Gilead Sciences' Letairis, Ambrisentan Tablets, got U.S. FDA approval in April 2019 from the Indian pharmaceutical company Cipla. This improved the company's portfolio. The need for better healthcare services in the area is also driven by the region's enormous population base and the expanding burden of diseases like HIV that cause hypertension.

In May 2022, Hanmi Pharmaceutical announced that it would begin marketing its blockbuster hypertension medicine Amosartan in China under the brand name Meiyaping. It was the first Chinese-made blood pressure combination medication to hit the market. In April 2021, Mineralys Therapeutics, a Radnor-based biopharmaceutical business, announced a $40 million private stock offering on Tuesday. Mineralys will use the funding to perform a phase 2 proof-of-concept trial for MLS-101, its lead experimental hypertension therapy. It also intends to use the funds to fund preliminary work for late-stage therapy testing.

Few of the players in the Hypertension Drugs Market include:

• Pfizer Inc.
• Novartis AG
• AstraZeneca plc
• Merck & Co., Inc.
• Sanofi S.A.
• Johnson & Johnson
• Bayer AG
• Boehringer Ingelheim
• Takeda Pharmaceutical Company Limited
• Daiichi Sankyo Company, Limited
• Bristol Myers Squibb Company
• Lupin Limited
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy’s Laboratories Ltd.

The Global Hypertension Drugs Market is Segmented as Below:

By Drug Class

• Diuretics
• ACE Inhibitors
• Angiotensin II Receptor Blockers
• Calcium Channel Blockers
• Beta Blockers
• Alpha Blockers
• Vasodilators
• Renin Inhibitors
• Combination Drugs
• Others

By Hypertension Type

• Primary Hypertension
• Secondary Hypertension
• Pulmonary Hypertension
• Resistant Hypertension
• Others

By Route of Administration

• Oral
• Injectable
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Specialty Pharmacies

By End User

• Hospitals
• Clinics
• Homecare Settings
• Ambulatory Care Centers
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa